Patents by Inventor Elias Georges

Elias Georges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6114376
    Abstract: This invention describes methods for increasing the toxicity of a cytostatic hydrophobic chemotherapeutic agent against resistant tumor cells in mammals which comprise administering a multidrug resistant reversing agent to the mammal in connection with the administration of the cytostatic hydrophobic chemotherapeutic agent in an amount effective to increase the toxicity of the chemotherapeutic agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound. Examples of the macrocyclic lactone compounds useful in the present invention include, but are not limited to, the LL-F28249.alpha.-.lambda. series of compounds, the 23-oxo or 23-imino derivative thereof, the avermectins, the 22,23-dihydro derivatives thereof and the milbemycins. Compositions comprising the macrocyclic lactone compounds and the chemotherapeutic agents are also described herein.
    Type: Grant
    Filed: April 28, 1998
    Date of Patent: September 5, 2000
    Assignee: McGill University
    Inventors: Roger K. Prichard, Jean-Fran.cedilla.ois Pouliot, Elias Georges
  • Patent number: 5223400
    Abstract: An immunoassay method for determining the specificity of binding of a monoclonal antibody to an antigen is afforded by comparing the binding of antibody and antigen both with and without the addition of excess epitope specific peptide.
    Type: Grant
    Filed: June 1, 1989
    Date of Patent: June 29, 1993
    Assignee: The Ontario Cancer Institute
    Inventors: Victor Ling, Elias Georges